The purpose of this study is to document the efficacy and safety profiles of single intravenous dose of 5 mg zoledronic acid for the Chinese patients of Paget's Disease of Bone (PDB).

Inclusion Criteria:

• Confirmed diagnosis of PDB by radiological reports
• Serum Alkaline Phosphatase level (SAP) at least two times the upper limit of the normal (ULN)

Exclusion Criteria:

• History of hypersensitivity to the active substance or to any of the excipients or to any bisphosphonates;
• History of malignancy of any organ system
• Severe liver or bladder disease;
• Calculated creatinine clearance < 35 mL/min at baseline;
• Hypocalcaemia;
• Patients with pre-existing dental diseases or who predict to have dental surgeries during the study;
• Evidence of vitamin D deficiency.

Other protocol-defined inclusion/exclusion criteria may apply.